Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA: Seizure, Alcohol Risk with Pfizer’s Chantix

By Drug Discovery Trends Editor | March 10, 2015

(Credit: AP Photo/Mark Lennihan)The U.S. Food and Drug Administration (FDA) has determined it will not reduce the severity of its black-box warning about side effects associated with Pfizer’s Chantix, reports Reuters. The smoking-cessation drug has been linked with psychiatric risks, including seizures, and aggressiveness and blacking out when patients drink while taking the drug.

Chantix, known chemically as varenicline, was approved in 2006. The FDA soon after updated the warning label to include side effects such as suicidal thoughts, hostility and agitation.

Pfizer has requested the FDA remove the black box, the most serious safety alert that can appear on product labeling. Although Pfizer has said its own studies do not support an association between Chantix and such severe side effects, an FDA advisory committee in October 2014 recommended leaving the black box alone awaiting the outcome of an ongoing safety study.

Establish your company as a technology leader. For 50 years, the R&D 100 Awards, widely recognized as the “Oscars of Invention,” have showcased products of technological significance. Learn more. 

Since then, the FDA has examined data, including Pfizer’s, and determined that these observational studies were limited. Pfizer is working on another safety study on the drug, and trial results are expected in late 2015.

In the meantime, the FDA said it will keep the black-box warning.

Sales of Chantix fell last year to $647 million from $846 million in 2008, and Pfizer spent hundreds of millions of dollars to settle lawsuits in the last several years, The Wall Street Journal’s Pharmalot blog reports. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority
Portrait photo of Pfizer EVP and Medtronic board member Lidia Fonseca
Medtronic appoints Pfizer EVP as independent board director

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50